TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Authors
Keywords
-
Journal
Nature Communications
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-12-18
DOI
10.1038/s41467-017-02358-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
- (2017) Daniel Zingg et al. Cell Reports
- TRAF2 multitasking in TNF receptor-induced signaling to NF-κB, MAP kinases and cell death
- (2016) Alice Borghi et al. BIOCHEMICAL PHARMACOLOGY
- Deubiquitination and Stabilization of PD-L1 by CSN5
- (2016) Seung-Oe Lim et al. CANCER CELL
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor-necrosis factor impairs CD4+ T cell–mediated immunological control in chronic viral infection
- (2016) Marc Beyer et al. NATURE IMMUNOLOGY
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- Blocking Tumor Necrosis Factor Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma
- (2015) F. Bertrand et al. CANCER RESEARCH
- Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4 + T- Cells, Which Dampen CD8 + T-cell Antitumor Reactivity
- (2015) Marco Donia et al. CANCER RESEARCH
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting TNF alpha as a novel strategy to enhance CD8+T cell-dependent immune response in melanoma?
- (2015) Florie Bertrand et al. OncoImmunology
- Essential versus accessory aspects of cell death: recommendations of the NCCD 2015
- (2014) L Galluzzi et al. CELL DEATH AND DIFFERENTIATION
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis
- (2013) Martin Chopra et al. CARCINOGENESIS
- Tumor Necrosis Factor-α Blocks Differentiation and Enhances Suppressive Activity of Immature Myeloid Cells during Chronic Inflammation
- (2013) Moshe Sade-Feldman et al. IMMUNITY
- Homogeneous Expansion of Human T-Regulatory Cells Via Tumor Necrosis Factor Receptor 2
- (2013) Yoshiaki Okubo et al. Scientific Reports
- Stromal Estrogen Receptor- Promotes Tumor Growth by Normalizing an Increased Angiogenesis
- (2012) C. Pequeux et al. CANCER RESEARCH
- TNF signaling drives myeloid-derived suppressor cell accumulation
- (2012) Xueqiang Zhao et al. JOURNAL OF CLINICAL INVESTIGATION
- Antigen-Independent Induction of Tim-3 Expression on Human T Cells by the Common -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Is Associated with Proliferation and Is Dependent on the Phosphoinositide 3-Kinase Pathway
- (2012) S. Mujib et al. JOURNAL OF IMMUNOLOGY
- Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
- (2012) Jennifer Landsberg et al. NATURE
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- Activation of mitogen activated protein kinase-Erk kinase (MEK) increases T cell immunoglobulin mucin domain-3 (TIM-3) transcription in human T lymphocytes and a human mast cell line
- (2011) Soo-Jin Yoon et al. MOLECULAR IMMUNOLOGY
- B regulatory cells and the tumor-promoting actions of TNF- during squamous carcinogenesis
- (2011) T. Schioppa et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started